GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Impact of concomitant fluconazole on direct oral anticoagulant bleeding risk
    Wiley ; 2022
    In:  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Vol. 42, No. 12 ( 2022-12), p. 880-889
    Details
    In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Wiley, Vol. 42, No. 12 ( 2022-12), p. 880-889
    Abstract: The aim of this study was to evaluate the effect on bleeding risk when fluconazole is administered concomitantly with direct oral anticoagulants (DOACs). Design This was a retrospective cohort study including hospitalized adult patients prescribed a DOAC with or without fluconazole. Setting The Ohio State University Wexner Medical Center, a tertiary care academic medical center with more than 1800 beds. Patients Hospitalized patients ages 18–89 years who received apixaban or rivaroxaban with or without fluconazole from October 1, 2016, to September 30, 2021, were included. The minimum duration of DOAC or DOAC with fluconazole therapy was 48 h. Patients were excluded if they received fluconazole 〈 400 mg daily or a DOAC at doses outside those recommended for atrial fibrillation or venous thromboembolism treatment or prophylaxis. Patients were matched based on DOAC received. Intervention Patients who received a DOAC with fluconazole were compared with those receiving a DOAC alone. The primary outcome was a composite of major, clinically relevant nonmajor, and minor bleeding events at 30 days. Measurements and Main Results There were 216 patients included, 108 in the DOAC with fluconazole group and 108 in the DOAC alone group. More patients in the DOAC with fluconazole group experienced bleeding at 30 days compared with the DOAC alone group [35/108 (32%) vs. 21/108 (19%), respectively; p  = 0.03]; however, after adjusting for proven confounding variables (hemoglobin and concomitant carvedilol) this was found not to be statistically significant [adjusted odds ratio 1.71, 95% confidence interval 0.85–3.40] . Conclusions Patients receiving a DOAC with fluconazole were not at significantly increased risk for bleeding at 30 days compared with those receiving a DOAC alone after controlling for confounding variables. As an increasing number of patients are prescribed DOACs, the results of this study may inform clinical decision‐making on the safety of concomitant DOAC and fluconazole use.
    Type of Medium: Online Resource
    ISSN: 0277-0008 , 1875-9114
    URL: Issue
    URL: Article
    DOI: 10.1002/phar.v42.12
    DOI: 10.1002/phar.2738
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2061167-5
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections
    Elsevier BV ; 2021
    In:  International Journal of Antimicrobial Agents Vol. 58, No. 2 ( 2021-08), p. 106363-
    Details
    In: International Journal of Antimicrobial Agents, Elsevier BV, Vol. 58, No. 2 ( 2021-08), p. 106363-
    Type of Medium: Online Resource
    ISSN: 0924-8579
    URL: Article
    DOI: 10.1016/j.ijantimicag.2021.106363
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2011829-6
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    1484. Impact of Combination Vs. Monotherapy on Clinical Outcomes Associated with Stenotrophomonas maltophilia Pneumonia
    Oxford University Press (OUP) ; 2018
    In:  Open Forum Infectious Diseases Vol. 5, No. suppl_1 ( 2018-11-26), p. S459-S459
    Details
    In: Open Forum Infectious Diseases, Oxford University Press (OUP), Vol. 5, No. suppl_1 ( 2018-11-26), p. S459-S459
    Type of Medium: Online Resource
    ISSN: 2328-8957
    URL: Article
    DOI: 10.1093/ofid/ofy210.1313
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2018
    detail.hit.zdb_id: 2757767-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    599. Association between Vancomycin AUC and Clinical Failure in Patients with Streptococcal Bacteremia
    Oxford University Press (OUP) ; 2022
    In:  Open Forum Infectious Diseases Vol. 9, No. Supplement_2 ( 2022-12-15)
    Details
    In: Open Forum Infectious Diseases, Oxford University Press (OUP), Vol. 9, No. Supplement_2 ( 2022-12-15)
    Abstract: Vancomycin (VAN) is an efficacious therapy against Streptococcus. VAN area under the curve to minimum inhibitory concentration (AUC/MIC) is the preferred monitoring strategy for serious methicillin-resistant S. aureus infections but is not well elucidated for other bacterial pathogens such as Streptococcus. Methods This was a retrospective cohort study evaluating adult inpatients with streptococcal bacteremia treated with VAN definitive therapy from Jan 1, 2011 to Sept 30, 2021 at a tertiary care academic medical center. VAN AUC was retrospectively calculated using Bayesian software (ClinCalc). The primary outcome was treatment failure, defined as a composite of recurrent or persistent streptococcal bacteremia, 60-day all-cause readmission, or 60-day all-cause mortality. Secondary outcomes included time to bacteremia clearance, hospital length of stay (LOS), and nephrotoxicity. Data collected included demographics; comorbidities; severity of illness; streptococcal species and source; VAN initial trough and duration; and clinical outcomes. Classification and regression tree analysis (CART) was conducted to identify the AUC threshold predictive of clinical failure. Wilcoxon rank sum, Chi Square, or Fisher’s exact tests were utilized as appropriate to compare groups stratified by the CART-identified AUC threshold. Results Forty-six patients met inclusion criteria during the study timeframe. Eleven patients had a VAN AUC & lt; 329 of which 8 (73%) experienced clinical failure, while 35 patients had a VAN AUC & gt; 329 of which 12 (34%) experienced clinical failure (p=0.04). No significant differences in baseline or clinical characteristics were identified between groups. Median VAN initial trough was higher in the VAN AUC & gt; 329 group (13.2 vs 6.2, p & lt; 0.001). Median hospital LOS was longer in the VAN AUC & gt; 329 group (15 vs 8 days, p=0.05) while median time to bacteremia clearance (29 vs 25 hrs, p=0.15) and nephrotoxicity incidence (13% vs 4%, p=1) were not significantly different. Conclusion Vancomycin AUC & lt; 329 was predictive of clinical failure in patients with streptococcal bacteremia. Larger studies are needed before VAN AUC monitoring can be recommended for implementation in the management of streptococcal bacteremia. Disclosures All Authors: No reported disclosures.
    Type of Medium: Online Resource
    ISSN: 2328-8957
    URL: Article
    DOI: 10.1093/ofid/ofac492.651
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 2757767-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    177. Clinical Outcomes of Daptomycin vs. Anti-Staphylococcal β-Lactams in Definitive Treatment of Methicillin-Susceptible Staphylococcus aureus (MSSA) Bloodstream Infections
    Oxford University Press (OUP) ; 2019
    In:  Open Forum Infectious Diseases Vol. 6, No. Supplement_2 ( 2019-10-23), p. S111-S111
    Details
    In: Open Forum Infectious Diseases, Oxford University Press (OUP), Vol. 6, No. Supplement_2 ( 2019-10-23), p. S111-S111
    Abstract: The preferred management of patients with MSSA bacteremia includes definitive therapy with intravenous anti-staphylococcal β-lactam antibiotics. In β-lactam allergic or intolerant patients, daptomycin has been targeted as a viable alternative. The objective of this study was to assess clinical outcomes of daptomycin compared with nafcillin or cefazolin for the treatment of MSSA bacteremia. Methods This was a retrospective cohort study of patients hospitalized from November 1, 2011 to October 31, 2018 at The Ohio State University Wexner Medical Center with MSSA bacteremia. Patients treated with nafcillin, cefazolin or daptomycin were included with 1:1:1 random selection. The primary outcome was a composite of clinical failure, defined as a change in therapy due to persistent/worsening signs and symptoms, bacteremia recurrence or persistence, or inpatient infection-related mortality. Secondary endpoints included 30-day infection-related mortality, duration of bacteremia, 30-day all-cause mortality and adverse events (AEs) necessitating a change in therapy. Results Among patients with MSSA bacteremia, 162 received at least one dose of daptomycin. Of those, 29 received at least 14 days of daptomycin and/or received daptomycin as definitive therapy and thus were included in the analysis. There was no difference in the primary outcome of composite clinical failure comparing daptomycin vs. nafcillin/cefazolin (P = 0.71). In addition, no difference was observed in 30-day infection-related mortality (P = 0.51), duration of MSSA bacteremia (P = 0.9), or 30-day all-cause mortality (P = 0.64). A higher number of AEs necessitating change in therapy were seen in the daptomycin group (P = 0.0002), reflecting initial β-lactam intolerance. Conclusion No difference in clinical failure was identified in patients treated with daptomycin vs. nafcillin/cefazolin suggesting that daptomycin may serve as a non-inferior alternative for treatment of MSSA bacteremia. A higher number of AEs occurred in the daptomycin group indicating β-lactam intolerance as a primary indication for daptomycin therapy. Given the small sample size, subsequent studies are needed to further evaluate the use of daptomycin in the treatment of MSSA bacteremia. Disclosures All authors: No reported disclosures.
    Type of Medium: Online Resource
    ISSN: 2328-8957
    URL: Article
    DOI: 10.1093/ofid/ofz360.252
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 2757767-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis
    Elsevier BV ; 2021
    In:  Diagnostic Microbiology and Infectious Disease Vol. 101, No. 3 ( 2021-11), p. 115504-
    Details
    In: Diagnostic Microbiology and Infectious Disease, Elsevier BV, Vol. 101, No. 3 ( 2021-11), p. 115504-
    Type of Medium: Online Resource
    ISSN: 0732-8893
    URL: Article
    DOI: 10.1016/j.diagmicrobio.2021.115504
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2026024-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Effectiveness of short vs long‐course perioperative antibiotics in lung transplant recipients with donor positive respiratory cultures
    Wiley ; 2021
    In:  Transplant Infectious Disease Vol. 23, No. 3 ( 2021-06)
    Details
    In: Transplant Infectious Disease, Wiley, Vol. 23, No. 3 ( 2021-06)
    Abstract: Lung transplant recipients are at increased risk for infection in the early postoperative phase, thus perioperative antibiotics are employed. This retrospective study evaluated the efficacy of short‐ vs long‐course perioperative antibiotics in lung transplant patients. Lung transplant patients with donor positive cultures between August 2013 and September 2019 were evaluated, excluding those with cystic fibrosis, death within 14 days and re‐transplants. The primary outcome was 30‐day freedom from donor‐derived respiratory infection. A total of 147 patients were included (57 short vs 90 long‐course). Median perioperative antibiotic duration was 6 days in the short‐course vs 14 days in the long‐course group ( P   〈  .0001). Thirty‐day freedom from donor‐derived respiratory infection was present in 56 (98%) patients in the short‐course vs 85 (94%) patients in the long‐course group ( P  = .41). There was no difference in development of Clostridioides difficile infections ( P  = .41), while cumulative ventilator time and time to post‐op extubation were longer in the long‐course group ( P  = .001 and .004, respectively). Among lung transplant recipients with positive donor respiratory cultures, short‐course perioperative antibiotics were as effective as long‐course antibiotics in preventing donor‐derived bacterial respiratory infections.
    Type of Medium: Online Resource
    ISSN: 1398-2273 , 1399-3062
    URL: Issue
    URL: Article
    DOI: 10.1111/tid.v23.3
    DOI: 10.1111/tid.13518
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2010983-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results
    American Society for Microbiology ; 2020
    In:  Journal of Clinical Microbiology Vol. 58, No. 5 ( 2020-04-23)
    Details
    In: Journal of Clinical Microbiology, American Society for Microbiology, Vol. 58, No. 5 ( 2020-04-23)
    Abstract: Clostridioides difficile infection (CDI) is one of the most common health care-associated infections that can cause significant morbidity and mortality. CDI diagnosis involves laboratory testing in conjunction with clinical assessment. The objective of this study was to assess the performance of various C. difficile tests and to compare clinical characteristics, Xpert C. difficile /Epi (PCR) cycle threshold ( C T ), and Singulex Clarity C. diff toxins A/B (Clarity) concentrations between groups with discordant test results. Unformed stool specimens from 200 hospitalized adults (100 PCR positive and 100 negative) were tested by cell cytotoxicity neutralization assay (CCNA), C. diff Quik Chek Complete (Quik Chek), Premier Toxins A and B, and Clarity. Clinical data, including CDI severity and CDI risk factors, were compared between discordant test results. Compared to CCNA, PCR had the highest sensitivity at 100% and Quik Chek had the highest specificity at 100%. Among clinical and laboratory data studied, prevalences of leukocytosis, prior antibiotic use, and hospitalizations were consistently higher across all subgroups in comparisons of toxin-positive to toxin-negative patients. Among PCR-positive samples, the median C T was lower in toxin-positive samples than in toxin-negative samples; however, C T ranges overlapped. Among Clarity-positive samples, the quantitative toxin concentration was significantly higher in toxin-positive samples than in toxin-negative samples as determined by CCNA and Quik Chek Toxin A and B. Laboratory tests for CDI vary in sensitivity and specificity. The quantitative toxin concentration may offer value in guiding CDI diagnosis and treatment. The presence of leukocytosis, prior antibiotic use, and previous hospitalizations may assist with CDI diagnosis, while other clinical parameters may not be consistently reliable.
    Type of Medium: Online Resource
    ISSN: 0095-1137 , 1098-660X
    URL: Article
    DOI: 10.1128/JCM.01681-19
    RVK:
    XA 10000
    Language: English
    Publisher: American Society for Microbiology
    Publication Date: 2020
    detail.hit.zdb_id: 1498353-9
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Clinical Outcomes with Penicillin Versus Alternative β‐Lactams in the Treatment of Penicillin‐Susceptible Staphylococcus aureus Bacteremia
    Wiley ; 2018
    In:  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Vol. 38, No. 7 ( 2018-07), p. 769-775
    Details
    In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Wiley, Vol. 38, No. 7 ( 2018-07), p. 769-775
    Abstract: To identify the impact of penicillin versus alternative β‐lactams on clinical outcomes in patients with penicillin‐susceptible Staphylococcus aureus ( PSSA ) bacteremia. Design Retrospective cohort study. Setting Academic medical center. Patients Adult patients with PSSA bacteremia treated with a β‐lactam as definitive therapy. Measurements The primary outcome was a composite end point of 30‐day clinical failure (change in PSSA therapy due to persistent or worsening signs and symptoms, PSSA bacteremia recurrence or persistence, and/or infection‐related mortality) in patients treated with penicillin versus alternative β‐lactams. Secondary outcomes included infection‐related and hospital length of stay ( LOS ), 90‐day recurrence, 90‐day infection‐related readmission, 30‐day all‐cause mortality, adverse drug events ( ADE s), and 30‐day change in PSSA therapy due to ADE s. A subgroup analysis comparing penicillin, nafcillin, and cefazolin was also conducted. Main Results For the 122 patients who were included, the most common definitive therapies were nafcillin (37%), cefazolin (29%), and penicillin (21%). No difference was found in 30‐day clinical failure (4% vs 11%, p=0.46), infection‐related LOS (12 days vs 11 days, p=0.39), hospital LOS (12.5 days vs 12 days, p=0.69), 90‐day recurrence (p=1.00), 90‐day infection‐related readmission (p=1.00), or 30‐day all‐cause mortality (p=0.45) between penicillin and other β‐lactams. The prevalence of ADE s was different among penicillin, nafcillin, and cefazolin (p=0.049), with nafcillin requiring more changes in therapy (p=0.005). Conclusions Definitive therapy with penicillin had similar efficacy compared with alternative β‐lactams for the treatment of PSSA bacteremia. However, nafcillin was associated with more ADE s requiring a change in therapy.
    Type of Medium: Online Resource
    ISSN: 0277-0008 , 1875-9114
    URL: Issue
    URL: Article
    DOI: 10.1002/phar.2018.38.issue-7
    DOI: 10.1002/phar.2124
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2061167-5
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Clinical Outcomes with Ertapenem for Pneumonia in Obese versus Nonobese Patients
    American Society for Microbiology ; 2022
    In:  Antimicrobial Agents and Chemotherapy Vol. 66, No. 1 ( 2022-01-18)
    Details
    In: Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 66, No. 1 ( 2022-01-18)
    Abstract: The objective of this study was to compare the rate of pneumonia resolution in obese (body mass index [BMI], ≥30 kg/m 2 ) and nonobese (BMI,  〈 30 kg/m 2 ) patients treated with 1 gram ertapenem daily. In this retrospective cohort study, we evaluated patients treated at The Ohio State University Wexner Medical Center between 1 January 2015 and 31 August 2020. Patients were included if they were between 18 and 89 years old and received ertapenem for at least 48 hours for pneumonia treatment. Patients were excluded if they were pregnant, were incarcerated, had renal impairment, received antibiotics with Gram-negative activity for a significant period prior to or in addition to ertapenem, and had other concomitant deep-seated infections. The primary outcome of clinical resolution was defined as meeting any of the following three criteria in order of evaluations: discontinuation of antibiotics by day 8 of therapy, afebrile while on ertapenem in addition to a decrease in white blood cell count, or improvement on chest radiograph at day 7 of therapy. A multivariable logistic regression analysis was performed to examine the association between obesity and clinical resolution, while adjusting for proven confounders. There were 76 nonobese and 65 obese patients included. The median patient BMI was 23.7 kg/m 2 (21.0 to 26.9) and 35.0 kg/m 2 (32.8 to 39.8) for the nonobese and obese cohorts, respectively. Clinical resolution was achieved in 78% (59/76) of nonobese and 75% (49/65) of obese patients ( P  = 0.75) without an observed difference in the regression model. Outcomes were similar in obese and nonobese patients treated with 1 gram of ertapenem daily for pneumonia.
    Type of Medium: Online Resource
    ISSN: 0066-4804 , 1098-6596
    URL: Article
    DOI: 10.1128/AAC.01325-21
    RVK:
    XA 24552
    Language: English
    Publisher: American Society for Microbiology
    Publication Date: 2022
    detail.hit.zdb_id: 1496156-8
    SSG: 12
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...